Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic
  • Search Hotels in Corte Madera

  • ROOMS:

Clover Reports COVID-19 Vaccine Meets Endpoints in Global Phase II/III Trial

Clover, a Chengdu vaccine/biologic company, reported its adjuvanted protein-based COVID-19 vaccine candidate met its endpoints in a global, 30,000 person pivotal Phase II/II trial. SCB-2019 (CpG 1018/Alum) prevented 100% of severe COVID-19 vaccine and hospitalizations in all SARS-CoV-2 strains. Overall efficacy was 67% against COVID-19 of any severity caused by any strain. It posted 79% overall efficacy against COVID-19 of any severity in Delta subjects. Clover's trial was supported by CEPI, the Coalition for Epidemic Preparedness Innovations. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.